Repligen (RGEN) PT Raised to $135 at Stifel
Tweet
Share
E-mailGet Alerts RGEN Hot Sheet
Price: $180.29 +2.23%
Rating Summary:
23 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
23 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
Stifel analyst Daniel Arias raised the price target on Repligen (NASDAQ: RGEN) to $135.00 (from $113.00) while maintaining a Buy rating.
You May Also Be Interested In
- Unicycive Therapeutics (UNCY) PT Raised to $15 at Benchmark Following Q2 Results
- NetEase.com (NTES) PT Lowered to $143 at Macquarie
- SentinelOne Inc (S) PT Raised to $26 at Cantor Fitzgerald Following Strong Q2 Checks
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
